During the three days the following will be explored in depth:

• the new frontiers of integrated diagnosis (ECG, echocardiography, magnetic resonance imaging and molecular genetics);
• le therapeutic strategies emerging, such as the myosin modulation and targeted inhibitors;
• le precision cardiac surgery indications;
• the use of multimodal imaging for risk stratification;
• the role of Patient associations in the care pathway and in the shared decision-making process.

AICARM APS wholeheartedly supports initiatives like this, which promote professional development and collaboration between clinicians, researchers, and patient associations.

Shared knowledge is the foundation for more personalized, informed, and humane medicine: a goal that AICARM pursues every day in its work alongside people with cardiomyopathy.